Monographie - Asparaginase - Stabilis 4.0

Son güncelleme :
19/11/2024

kanser ilaç

Asparaginase

Enjeksiyon

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

pdf

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Elspar	Amerika Birleşik Devletleri, Meksika
Kidrolase	Arjantin, Bulgaristan, Ekvador, Fas, İsrail, Kanada, Kolombiya, Mısır, Şili, Suudi Arabistan, Türkiye
L Aspase	Hindistan
Laspar	Güney Afrika Cumhuriyeti
Leunase	Avustralya, Japonya, Malezya, Meksika
Paronal	Belçika, Hollanda, İtalya
Spectrila	Fransa

Kaynaklar

Enjeksiyon

Kaynaklar : Asparaginase

	tip	yayın
150	Dergi	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
1858	Dergi	Stecher AL, Morgantetti de Deus P, Polikarpov I, Abrahao-Neto J. Stability of L-asparaginase: an enzyme used in leukemia treatment. Pharm Acta Helv 1999 ; 74: 1-9.
2148	Dergi	Lanvers C, Pinheiro JPV, Hempel G, Wuerthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002 ; 309: 117-126.
3128	Laboratuar	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3243	afiş	Nicolson O, d'Hayer B, Vieillard V, Dollet S, Astier A, Paul M. Stability of diluted L-asparaginase in normal saline solution. ECCO Congress Stockholm 2011
3686	Laboratuar	L asparaginase (Kidrolase®) - Résumé des caractéristiques du produit Eusapharma 2013
4471	Laboratuar	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019

Mentions Légales